IDEXX Laboratories Inc (IDXX)vsiSpecimen Inc (ISPC)
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
ISPC
iSpecimen Inc
$3.00
-2.28%
HEALTHCARE · Cap: $4.34M
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 432610% more annual revenue ($4.45B vs $1.03M). IDXX leads profitability with a 24.6% profit margin vs 0.0%. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
ISPC
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Margin of Safety
+60.8%
Fair Value
$0.79
Current Price
$3.00
$2.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : ISPC
The strongest argument for ISPC centers on Price/Book.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Bear Case : ISPC
The primary concerns for ISPC are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
IDXX profiles as a mature stock while ISPC is a value play — different risk/reward profiles.
ISPC carries more volatility with a beta of 1.62 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (234M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 15/100), backed by strong 24.6% margins and 14.3% revenue growth. ISPC offers better value entry with a 60.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
iSpecimen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?